NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company’s share has been upgraded to trading on the OTC Market Group’s best market, OTCQX in the US. The upgrade implies increased accessibility and transparency for US investors and potential partners in the world’s largest pharmaceutical market. Since March 2014, US investors have been able to trade NeuroVive shares online on the OTC market. The shares became quoted on the Pink Market in June 2015. The subsequent upgrade to OTCQX represents a further seal of approval as there are increased regulatory requirements that enable trading and companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications. The upgrade is a part of NeuroVive’s strategic focus on increasing its presence in the US and raising awareness of the company amongst investors and potential partners. NeuroVive’s current projects include a pre-clinical study in traumatic brain injury (TBI) alongside prestigious University of Pennsylvania (PENN). “US interest in NeuroVive has increased in recent years, and we believe that the upgrade to OTCQX will help to accelerate this trend as we move forward. Awareness of the company is likely to increase further in the US as our development programs progress, including those carried out alongside US partners. It’s important to have a presence on a credible and well-functioning trading platform in order to convert that interest into strengthening our international ownership structure,” commented NeuroVive’s CEO Erik Kinnman. The NeuroVive share is registered with OTC’s reporting service for foreign securities in New York under the ticker symbol NEVPF:US. NEVPF’s share price can be monitored at www.otcmarkets.com or through US brokers. About OTC Markets Group Inc. OTC Markets Group Inc. (http://www.otcmarkets.com/stock/OTCM/quote?utm_source=Press%20Release&utm_ m edium=Press%20Release&utm_campaign=Press%20Release) (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS. About OTCQX International The OTCQX Best Market is for established, global and growth companies, operated by OTC Markets Group. To qualify for the OTCQX Best Market, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications. For more information, please visit www.otcmarkets.com. About NeuroVive NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden. For investor relations and media questions, please contact: Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 info@neurovive.com, www.neurovive.com NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 2 June 2016, at 13.00 CET. NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. Investors can find Real-Time quotes and market information for the company at www.otcmarkets.com/stock/NEVPF/quote
NeuroVive share upgraded to OTC Markets Group – OTCQX
Top 10 Most Recent News Articles
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof
Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...
Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification
Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...
Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus
An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...
Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet
Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...
Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test
A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...
Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure
One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...
Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus
Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...
Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real
GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...
Continue Reading
Align Wagner Collection Tests Men's Footwear Depth
Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...
Continue Reading
Human Frontier Mission Puts AI Research on Display
A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...
Continue ReadingTop 5 Most Recently Viewed Articles
Frontline Healthcare Partners Secures Integracare Inc. Deal
Frontline Healthcare Partners Expands Through Strategic Acquisition Frontline Healthcare Partners has recently made headlines with its strategic acquisition of Integracare Inc.. This move indicates a significant step forward in enhancing its portfolio within the private home healthcare space. With Integracare’s reputation for quality care in Toronto and Mississauga,...
Continue Reading
WiMi Innovates with Advanced FPGA-Based Quantum Computing Tech
WiMi Hologram Cloud Inc. Develops Cutting-Edge Quantum Computing Technology WiMi Hologram Cloud Inc. (NASDAQ: WiMi), a global leader in Hologram Augmented Reality (AR) technology, has achieved a remarkable milestone by developing a digital quantum computer verification technology based on Field-Programmable Gate Array (FPGA). This advancement signifies a transformative...
Continue Reading
KSP Achieves Excellence in Specialty Pharmacy Recognition Again
KSP Recognized as a Specialty Pharmacy Leader KSP, part of McLaren's Specialty Pharmacy, has once again been honored for its outstanding achievements in performance measurement. The Utilization Review Accreditation Commission (URAC) has recognized KSP as a 2024 Specialty Pharmacy Pioneer in its Leaders in Performance Measurement (LPM) program. This accolade underlines...
Continue Reading
Why IREN Limited Shares Are Under Pressure Today in Market
Understanding the Recent Drop in IREN Limited Stock IREN Limited (NASDAQ: IREN) has experienced a noticeable decline in share price today as investors react to the company's recent announcements. This comes as a surprise to some, as IREN has shown potential for growth in the past year. Recent Announcements from IREN Limited In a recent update, IREN Limited unveiled plans...
Continue Reading
Deutsche Bank Adjusts S&P 500 Forecast to 5,750 Points
Deutsche Bank Updates S&P 500 Year-End Forecast Deutsche Bank has adjusted its year-end target for the S&P 500 index, now forecasting it to reach 5,750 points, up from the previous estimate of 5,500. This significant change stems from strong corporate earnings, an increase in stock buybacks, and a solid demand for equities among investors. Positive Earnings Growth Ahead...
Continue Reading